Solving the Hypothyroidism Puzzle: Q&A: Antonio Bianco, MD, PhD
Two months after his new book, Rethinking Hypothyroidism, hit the shelves, Antonio Bianco, MD, PhD, talks to Endocrine News about, well, rethinking hypothyroidism. From his research of thyroid metabolism and deiodinases to why researchers and clinicians have often been so mystified by hypothyroidism for centuries, Bianco discusses why treating hypothyroidism is a “solution followed by...
Pro Golfer Azahara Muñoz Shares Her Experience with Hashimoto’s Disease
When professional golfer Azahara Muñoz started developing symptoms of Hashimoto’s thyroiditis – tiredness, cold extremities – she chalked them up to practicing too hard or traveling too much. It’s a stressful job. “You almost always have an excuse for it,” she says. But then around 2016, Muñoz noticed she began suffering from anxiety. Her hair...
New Data Show Strong Performance of Thyroid Cancer Test in Real-World Clinical Practice
Meta-analysis presented at ENDO 2022 provides real-world evidence that a test can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, and higher than that reported in the test’s original clinical validation (CV) study. Veracyte is...
Test Patterns: How Thyroid Nodule Tests Can Eliminate Needless Procedures
New research of genetic testing for thyroid nodules shows that they can make a substantial difference in patient outcomes, not to mention eliminating the need for unnecessary surgeries and biopsies. Then why aren’t more patients choosing to be tested? Let’s face it: no one likes taking tests. Then again, no one particularly enjoys going under...
New Integrated Data Show Promise for Novel Thyroid Eye Disease Drug
New pooled data from Phase 2 and Phase 3 clinical trials further reinforce that teprotumumab-trbw significantly improves proptosis (eye bulging) and diplopia (double vision) for thyroid eye disease (TED) in patients in different subgroups, with most maintaining a long-term response. The results were published recently in The Lancet Diabetes & Endocrinology. Teprotumumab-trbw is a fully human...
Small study finds 65% of patients taking teprotumumab report otologic symptoms. More patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for thyroid eye disease TED), teprotumumab (Tepezza), according to a small study presented virtually at ENDO 2021. Teprotumumab, approved by the U.S. Food and...
Combination Thyroid Hormone Therapies Treat Hypothyroidism Comparable to Levothyroxine
Treatment should be individualized for common thyroid condition, researchers say Treatment of hypothyroidism, which results from an underactive thyroid gland, should be individualized and consideration should be given to alternatives to the first-line therapy, including desiccated thyroid extract and combination therapy to replace the body’s two main thyroid hormones, thyroxine (T4) and triiodothyronine (T3), according...
FDA Grants Orphan Drug Designation for Potential Treatment of Hypoparathyroidism
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AZP-3601, Amolyt Pharma’s clinical candidate for the treatment of hypoparathyroidism. “We believe the FDA’s granting of Orphan Drug Designation to AZP-3601 reflects the agency’s recognition that new and more effective treatment options are needed for this serious endocrine disorder,” says Endocrine...
Endocrine News provides the latest news and research articles on thyroid conditions and treatment. For more info read this month’s issue of Endocrine News.